Range
48.93 - 52.37
Vol / Avg.
319.9K/437.5K
Div / Yield
-
52 Wk
25.43 - 91.92
Mkt Cap
2.3B
Payout Ratio
-
Open
51.94
P/E
-
EPS
-0.29
Shares
45M
Outstanding
45M
Total Float
-
Benzinga - 3 days ago
Benzinga - May 26, 2021, 9:04AM
Benzinga - May 21, 2021, 6:39AM
Benzinga - May 18, 2021, 10:06AM
Benzinga - May 12, 2021, 1:00PM
Benzinga - May 10, 2021, 9:03AM
Benzinga - May 6, 2021, 7:31AM
Benzinga - May 3, 2021, 4:01PM
Benzinga - May 3, 2021, 8:12AM
Benzinga - Apr 14, 2021, 10:14AM
Benzinga - Apr 14, 2021, 7:47AM
Benzinga - Apr 12, 2021, 10:25AM
Benzinga - Apr 9, 2021, 7:31AM
Benzinga - Mar 23, 2021, 7:54AM
Benzinga - Mar 11, 2021, 1:49PM
Benzinga - Mar 11, 2021, 7:08AM
Benzinga - Mar 2, 2021, 7:14AM
Benzinga - Jan 19, 2021, 9:29AM
load more
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

Earnings

see more
Q2 2021Est.ActualSurprise
EPS
(EXPECTED)2021-08-08
REV
Q1 2021Est.ActualSurprise
EPS-0.190-0.290 -0.1000
REV19.800M18.702M-1.098M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Related Companies

TickerCompanyChg %Mkt Cap
KYMRKymera Therapeutics-2.69%2.3B

Kymera Therapeutics Frequently Asked Questions

Q

How do I buy Kymera Therapeutics (KYMR) stock?

A

You can purchase shares of Kymera Therapeutics (NASDAQ: KYMR) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Kymera Therapeutics's (KYMR) competitors?

A

There are no as such competitors for Kymera Therapeutics.

Q

What is the target price for Kymera Therapeutics (KYMR) stock?

A

The latest price target for Kymera Therapeutics (NASDAQ: KYMR) was reported by UBS on May 21, 2021. The analyst firm set a price target for 80.00 expecting KYMR to rise to within 12 months (a possible 58.26% upside). 11 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Kymera Therapeutics (KYMR)?

A

The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $50.55 last updated Fri Jun 11 2021 20:00:02 GMT+0000 (Coordinated Universal Time).

Q

Does Kymera Therapeutics (KYMR) pay a dividend?

A

There are no upcoming dividends for Kymera Therapeutics.

Q

When is Kymera Therapeutics (NASDAQ:KYMR) reporting earnings?

A
Kymera Therapeutics’s Q2 earnings are confirmed for after-market on August 8, 2021.
Q

Is Kymera Therapeutics (KYMR) going to split?

A

There is no upcoming split for Kymera Therapeutics.

Q

What sector and industry does Kymera Therapeutics (KYMR) operate in?

A

Kymera Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.